Clinical trial documentation: regulatory-grade Czech translation across five release cycles

The client

A global medical device manufacturer running a multi-center clinical trial with sites in the Czech Republic. Translations were required for the patient-facing materials (informed consent forms, patient diaries, recruitment materials) and for the regulatory submissions to the Czech State Institute for Drug Control (SÚKL).

The challenge

Three constraints converged. First, the regulatory bar: every translation needs to pass scrutiny by Czech regulators who are detail-oriented and have a long memory for past linguistic issues. Second, the protocol was amended four times during the trial — every amendment required a fresh translation pass with full back-compatibility to previous translations already approved by ethics committees. Third, the client’s prior translation provider had delivered a TM with inconsistent terminology that was now baked into approved documents and could not be retroactively changed.

I had to translate forward, in fully consistent Czech, while preserving terminology decisions made — and documented as approved — in earlier rounds.

The approach

Pre-engagement audit. Reviewed the existing TM segment by segment. Documented every terminology choice that I would have made differently, classifying each as either (a) carry-forward (legacy approved, must preserve), (b) corrigible (can be improved without breaking compatibility), or (c) source-error (the English source itself was ambiguous and the Czech inherited the ambiguity). Delivered the audit with recommendations to the client’s regulatory affairs lead.

Per-amendment workflow. For each protocol amendment:

1. Source diff received from the client’s regulatory writer.
2. I translated only the changed segments, with explicit review of unchanged-but-affected segments where terminology context might shift.
3. Two-pass QA: linguistic, then a final cross-check against every previously approved document.
4. Delivery with a structured change log mapping every translated segment to the source diff.

Documentation discipline. Every editorial decision documented in a per-amendment translator’s note that became part of the regulatory submission package. The Czech regulator received not just translations, but a clear explanation of how each amendment’s translations related to those previously approved.

Tools used

memoQ (with locked TM segments for previously-approved content), Microsoft Word with track changes for client review cycles, structured Excel logs of every editorial decision, secure file transfer per the client’s IT requirements (no email attachments for any patient-facing documents).

Outcome

All five amendments delivered on time relative to the client’s regulatory submission schedule. SÚKL review of the Czech-language submission package raised zero queries on linguistic grounds across all five rounds — the regulator’s only feedback was on protocol substance, not on the translation. The client’s regulatory affairs lead identified the per-amendment translator’s notes as a model practice and adopted it for their other Central European market submissions.